ProCE Banner Activity


Ensuring Optimal Clinical Benefit From Oral SERD Therapy in Patients With HR+/HER2- Breast Cancer


Join expert faculty as they discuss implementation, benefits, and barriers to oral SERD therapies in patients with HR-positive/HER2-negative breast cancer. 

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Released: March 07, 2024

Expiration: March 06, 2025



Manali Bhave

Manali Bhave, MD

Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jamie L. Carroll

Jamie L. Carroll, CNP, APRN, MSN

Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC, in partnership with Practicing Clinicians Exchange and ProCE, LLC.

ProCE Banner


This activity is supported by an educational grant from Lilly.



Practicing Clinicians Exchange

ProCE Banner


ProCE Banner

Target Audience

This program is intended for oncology physician associates/nurse practitioners, oncology nurses, and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners to optimize clinical benefit by maintaining adherence and persistence with oral SERDs in the treatment of patients with HR+/HER2- breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan treatment for patients with HR+/HER2- MBC progressing on first-line endocrine therapy with or without CDK4/6 inhibitor based on individual patient and disease characteristics, genomic profile, available clinical data, new approvals, and expert recommendations

  • Mitigate and manage toxicities associated with oral SERD therapy for patients with HR+/HER2- breast cancer

  • Implement recommended strategies to improve adherence to oral SERD therapy in patients with HR+/HER2- breast cancer

  • Employ effective techniques to address factors leading to early discontinuation of oral anticancer therapy for the prescribed duration of treatment in patients with HR+/HER2- breast cancer


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Manali Bhave, MD

Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Manali Bhave, MD: consultant/advisor/speaker: DSI/AstraZeneca, Lilly, Merck, Novartis, Pfizer.

Jamie L. Carroll, CNP, APRN, MSN

Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Jamie L. Carroll, CNP, APRN, MSN: consultant/advisor/speaker: AstraZeneca, Lilly, Novartis.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 07, 2024, through March 06, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until March 06, 2025. PAs should only claim credit commensurate with the extent of their participation.